Matthijs M. Tibben

1.9k total citations
58 papers, 1.5k citations indexed

About

Matthijs M. Tibben is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Matthijs M. Tibben has authored 58 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 18 papers in Molecular Biology and 16 papers in Pathology and Forensic Medicine. Recurrent topics in Matthijs M. Tibben's work include Chemotherapy-induced organ toxicity mitigation (16 papers), Cancer therapeutics and mechanisms (12 papers) and Drug Transport and Resistance Mechanisms (11 papers). Matthijs M. Tibben is often cited by papers focused on Chemotherapy-induced organ toxicity mitigation (16 papers), Cancer therapeutics and mechanisms (12 papers) and Drug Transport and Resistance Mechanisms (11 papers). Matthijs M. Tibben collaborates with scholars based in Netherlands, Spain and Germany. Matthijs M. Tibben's co-authors include Jos H. Beijnen, Jan H.M. Schellens, Hilde Rosing, Dick Pluim, Alwin D. R. Huitema, Sjoerd Rodenhuis, Alfred H. Schinkel, Gianni Sava, Paul Baas and Erik van Werkhoven and has published in prestigious journals such as Cancer Research, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Matthijs M. Tibben

55 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matthijs M. Tibben Netherlands	21	832	428	242	184	175	58	1.5k
Frédéric Pinguet France	24	636 0.8×	575 1.3×	273 1.1×	113 0.6×	235 1.3×	95	1.8k
Alain Deroussent France	21	402 0.5×	529 1.2×	140 0.6×	98 0.5×	132 0.8×	47	1.5k
Manuel Álvarez Chile	24	879 1.1×	774 1.8×	126 0.5×	151 0.8×	233 1.3×	63	2.1k
Ashkan Emadi United States	22	770 0.9×	1.2k 2.8×	423 1.7×	185 1.0×	192 1.1×	108	2.9k
Benjamin Winograd Netherlands	21	1.3k 1.6×	928 2.2×	193 0.8×	223 1.2×	168 1.0×	56	2.3k
Lorraine K. Webster Australia	28	1.1k 1.3×	407 1.0×	391 1.6×	104 0.6×	183 1.0×	69	1.7k
Yong‐ju Liang China	27	1.4k 1.6×	1.1k 2.6×	306 1.3×	115 0.6×	284 1.6×	43	2.2k
Giuseppe Corona Italy	30	1.1k 1.3×	1.7k 3.9×	146 0.6×	122 0.7×	234 1.3×	109	3.0k
Christine M. Walko United States	24	992 1.2×	473 1.1×	60 0.2×	235 1.3×	454 2.6×	84	2.0k
Maki Hasegawa Japan	27	622 0.7×	701 1.6×	364 1.5×	114 0.6×	122 0.7×	68	2.2k

Countries citing papers authored by Matthijs M. Tibben

Since Specialization

Citations

This map shows the geographic impact of Matthijs M. Tibben's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthijs M. Tibben with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthijs M. Tibben more than expected).

Fields of papers citing papers by Matthijs M. Tibben

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthijs M. Tibben. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthijs M. Tibben. The network helps show where Matthijs M. Tibben may publish in the future.

Co-authorship network of co-authors of Matthijs M. Tibben

This figure shows the co-authorship network connecting the top 25 collaborators of Matthijs M. Tibben. A scholar is included among the top collaborators of Matthijs M. Tibben based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthijs M. Tibben. Matthijs M. Tibben is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tibben, Matthijs M., et al.. (2025). Imatinib Desensitization After a Type IV Hypersensitivity Reaction in a Gastrointestinal Stromal Tumor Patient—A Case Report. Cancer Reports. 8(6). e70238–e70238.

Jong, Daniëlle de, et al.. (2024). Interplay of Ritonavir-Boosted Oral Cabazitaxel with the Organic Anion-Transporting Polypeptide (OATP) Uptake Transporters and Carboxylesterase 1 in Mice. Molecular Pharmaceutics. 21(4). 1952–1964. 1 indexed citations

Sparidans, Rolf W., et al.. (2024). Brain Exposure to the Macrocyclic ALK Inhibitor Zotizalkib is Restricted by ABCB1, and Its Plasma Disposition is Affected by Mouse Carboxylesterase 1c. Molecular Pharmaceutics. 21(10). 5159–5170.

Jong, Daniëlle de, et al.. (2023). Enhancement of the Oral Availability of Cabazitaxel Using the Cytochrome P450 3A (CYP3A) Inhibitor Ritonavir in Mice. Molecular Pharmaceutics. 20(5). 2477–2489. 2 indexed citations

Vos‐Kerkhof, Evelien de, Catherine F. Enters-Weijnen, Marianne D. van de Wetering, et al.. (2022). Overestimation of the effect of (fos)aprepitant on intravenous dexamethasone pharmacokinetics requires adaptation of the guidelines for children with chemotherapy-induced nausea and vomiting. Supportive Care in Cancer. 30(12). 9991–9999. 4 indexed citations

Tibben, Matthijs M., et al.. (2021). Simultaneous quantification of abemaciclib and its active metabolites in human and mouse plasma by UHPLC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis. 203. 114225–114225. 18 indexed citations

Jong, Daniëlle de, Maria C. Lebre, Hilde Rosing, et al.. (2021). P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib. Molecular Pharmaceutics. 18(12). 4371–4384. 13 indexed citations

Tibben, Matthijs M., Hilde Rosing, Evelien de Vos‐Kerkhof, et al.. (2021). Development and validation of a combined liquid chromatography tandem-mass spectrometry assay for the quantification of aprepitant and dexamethasone in human plasma to support pharmacokinetic studies in pediatric patients. Journal of Chromatography B. 1171. 122639–122639. 6 indexed citations

Tibben, Matthijs M., et al.. (2020). Development and validation of an LC-MS/MS method for the quantitative analysis of milciclib in human and mouse plasma, mouse tissue homogenates and tissue culture medium. Journal of Pharmaceutical and Biomedical Analysis. 190. 113516–113516. 5 indexed citations

10.

Rosing, Hilde, et al.. (2019). Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry. Analytical and Bioanalytical Chemistry. 411(20). 5331–5345. 49 indexed citations

11.

Hoppe, Stéphanie van, Hilde Rosing, Maria C. Lebre, et al.. (2019). P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability. Molecular Pharmaceutics. 16(9). 3842–3852. 34 indexed citations

12.

Rosing, Hilde, Rubin Lubomirov, Pablo Avilés, et al.. (2018). Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine. Journal of Pharmaceutical and Biomedical Analysis. 158. 160–165. 5 indexed citations

13.

Fudio, Salvador, Hilde Rosing, Simon Munt, et al.. (2017). Pharmacokinetics and excretion of 14C–Plitidepsin in patients with advanced cancer. Investigational New Drugs. 35(5). 589–598. 11 indexed citations

14.

Brouwers, E. E. M., Matthijs M. Tibben, Hilde Rosing, Jan H.M. Schellens, & Jos H. Beijnen. (2008). The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research. Mass Spectrometry Reviews. 27(2). 67–100. 70 indexed citations

15.

Brouwers, E. E. M., Matthijs M. Tibben, Hilde Rosing, et al.. (2006). Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate. Journal of Mass Spectrometry. 41(9). 1186–1194. 51 indexed citations

16.

Brouwers, E. E. M., Matthijs M. Tibben, Markus Joerger, et al.. (2005). Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry. Analytical and Bioanalytical Chemistry. 382(7). 1484–1490. 23 indexed citations

17.

Tibben, Matthijs M., Jeany M. Rademaker-Lakhai, James A. Rice, et al.. (2002). Determination of total platinum in plasma and plasma ultrafiltrate, from subjects dosed with the platinum-containing N-(2-hydroxypropyl)methacrylamide copolymer AP5280, by use of graphite-furnace Zeeman atomic-absorption spectrometry. Analytical and Bioanalytical Chemistry. 373(4-5). 233–236. 21 indexed citations

18.

Huitema, Alwin D. R., et al.. (2001). Sensitive gas chromatographic determination of the cyclophosphamide metabolite 2-dechloroethylcyclophosphamide in human plasma. Journal of Chromatography B Biomedical Sciences and Applications. 757(2). 349–357. 9 indexed citations

19.

Huitema, Alwin D. R., et al.. (2001). Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high‐dose chemotherapy. British Journal of Clinical Pharmacology. 51(1). 61–70. 23 indexed citations

20.

Terwogt, Jetske M. Meerum, et al.. (2000). Validated method for the determination of platinum from a liposomal source (SPI-77) in human plasma using graphite furnace Zeeman atomic absorption spectrometry. Fresenius Journal of Analytical Chemistry. 366(3). 298–302. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact